JS Capital Management
VC Fund
New York, United States
JS Capital Management is an investment firm.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries JS Capital Management invests in
Stages JS Capital Management invests in
Countries JS Capital Management invests in
Round sizes
Round size
- Series C
- $83M–$276M
- Series D
- $120M–$125M
- Series E
- $150M–$400M
Investment Focus
Industry
- Life Science 2 (25%)
- Biotechnology 2 (25%)
- Sustainability 2 (25%)
- Financial Services 2 (25%)
- Music 1 (13%)
Stage
- Series C 2 (25%)
- Series D 2 (25%)
- Series E 2 (25%)
- Funding Round 1 (13%)
- Venture - Series Unknown 1 (13%)
Country
- United States 4 (50%)
- Japan 1 (13%)
- Sweden 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Closed Loop Partners invests in sustainable consumer goods, advanced recycling technologies and the development of the circular economy. | Feb 10, 2025 | ||
| Soundtrack Your Brand is a Spotify joint venture and the exclusive provider of Spotify Business and Spotify Enterprise. We connect brands and fans, and our vision is to grow the music market and thereby support artists, so that they can give the world more great music | $15M / Venture - Series Unknown / Jun 14, 2023 | ||
| Plenty is a vertical farming company that brings fresh, clean, and craveable produce to people everywhere. Plenty's vertical farms a fraction of the water and land required in conventional farming, are pesticide-free, and produce zero fertilizer runoff.Plenty is a collective of growers, innovators, engineers, scientists, artists, foodies,and plant romantics working to improve the health of plants, people, and the planet.It was founded in 2014 and headquartered in South San Francisco, California. | $400M / Series E / Jan 25, 2022 | ||
| Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. We are developing a modular and high-performing DNA sequencing platform that will deliver high quality data, workflow flexibility, and make next-generation sequencing technology more accessible. Our proprietaryapproach to improve the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation and biochemistry to drastically decrease the run cost and capital cost while delivering high sequencing data quality. | $276M / Series C / Jun 29, 2021 | ||
| Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $150M / Series E / Apr 05, 2021 | ||
| Paidy is a software platform that allows consumers to buy online without a credit card or pre-registration. It is optimized for mobile and instant-checkout, Paidy allows consumers to buy online and does not require a credit card or pre-registration.Paidy's payment service allows users to make purchases online, and then pay for them eachmonth in a consolidated bill. The company uses proprietary technology to score creditworthiness, underwrite transactions and guarantee payment to merchants. Since many Japanese consumers prefer not to use credit cards for online payments, Paidy’s service can help vendors increase their conversion rates, average order values and repeat purchases. | $120M / Series D / Mar 31, 2021 | ||
| Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $125M / Series D / Dec 10, 2019 | ||
| Paidy is a software platform that allows consumers to buy online without a credit card or pre-registration. It is optimized for mobile and instant-checkout, Paidy allows consumers to buy online and does not require a credit card or pre-registration.Paidy's payment service allows users to make purchases online, and then pay for them eachmonth in a consolidated bill. The company uses proprietary technology to score creditworthiness, underwrite transactions and guarantee payment to merchants. Since many Japanese consumers prefer not to use credit cards for online payments, Paidy’s service can help vendors increase their conversion rates, average order values and repeat purchases. | $83M / Series C / Nov 01, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does JS Capital Management invest in?
JS Capital Management invests primarily in Life Science, Biotechnology and Sustainability startups, most often at Series C and Series D stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is JS Capital Management's check size?
JS Capital Management typically joins rounds of $83M–$276M at Series C, $120M–$125M at Series D and $150M–$400M at Series E. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds JS Capital Management participates in.
When did JS Capital Management last invest?
The most recent investment recorded for JS Capital Management closed in Feb 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
